Week 16, 2018pdf, World Health Organization, SouthEast Asia Regional Office

(1)

Data Sources: Ministries of Health in SEAR Countries.

Published by

Immunization & Vaccine Development

, World Health Organization, Regional Office for South-East Asia, New Delhi

–

110002, India

Tel: 91-11-2337-0804 / 91-11-4304-0000 Fax: 91-11-2337-0251 / 0106 E-mail: [email protected], URL:

http://www.searo.who.int/topics/immunization/

Vol. 22, Week 16, 2018

Published 23 April 2018

Meetings/ Important events:



Ninth meeting of SEAR Immunization Technical Advisory Group (SEAR-ITAG), New Delhi, 17 to 20 July 2018



Third Meeting of the South-East Asia Regional Verification Commission for Measles Elimination and Rubella/ CRS Control (SEA-RVC),

Kathmandu, Nepal, 31 July to 2 August 2018

Table 1: Measles & Rubella Laboratory Supported Case-based Surveillance Performance Indicators by Country, 2018* (data as of 23 April 2018)

Table 2: Measles & Rubella Laboratory Supported Case-based Surveillance Performance Indicators by Country, 2017* (data as of 23 April 2018)

La

b

o

ra

to

ry

-c

o

n

fi

rm

e

d

E

p

id

e

m

io

lo

g

ic

a

ll

y-co

n

fi

rm

e

d

C

li

n

ic

a

ll

y-co

m

p

a

ti

b

le

La

b

o

ra

to

ry

-c

o

n

fi

rm

e

d

E

p

id

e

m

io

lo

g

ic

a

ll

y-co

n

fi

rm

e

d

Bangladesh 8,025 94 81 6,467 100 100 64 2,612 982 407 240 59 3,725 0 2.28 58 24.54 1.83

Bhutan 439 91 90 263 79 100 38 30* 0 0 3 0 406 0 51.38 90 37.96 3.80

DPR Korea 105 100 100 105 100 100 99 0 0 0 0 0 105 0 0.43 ND 0.00 0.00

India3 _21,391 ₀ ₃₁ _6,493 ₉₅ ₈₇ ₅₉ _3,268 _7,693 ₀ ₇₄₇ _2,112 _2,866 _4,705 _0.21 ₃ _8.19 _2.14

Indonesia4

13,215 0 99 13,032 97 99 36 4,636 0 6 4,320 0 4,082 171 1.56 16 17.72 16.50

Maldives 66 97 100 66 100 100 71 1* 0 0 1 0 64 0 18.91 60 2.95 2.95

Myanmar 1,785 40 90 1,610 99 100 93 1,032 208 77 6 0 462 0 0.88 15 25.21 0.11

Nepal 1,033 96 91 942 40 100 71 64 22 13 21 0 911 2 3.18 59 3.46 0.73

Sri Lanka 242 98 89 212 92 100 64 1 0 22 2 0 217 0 1.03 19 62.00 0.42

Thailand 2,979 28 85 2,418 59 95 60 1,467 9 579 24 0 806 94 1.23 ND 31.26 0.37

Timor-Leste 134 100 99 133 100 99 67 0 0 0 5 0 129 0 9.98 38 0.00 3.87

SEAR 49,414 22 65 31,741 93 97 53 13,111 8,914 1,104 5,369 2,171 13,773 4,972 0.70 11.81 3.85

1_{Includes labo rato ry-co nfirmed, epidemio lo gically-linked and clinically-co nfirmed measles cases} 4_{A lso includes the cases fro m enhanced measles case-based surveillance.}

ND=No data

2_{Includes labo rato ry-co nfirmed and epidemio lo gically-linked rubella cases}

* Impo rted cases

3 Case based surveillance is in the pro cess o f expansio n to all o ver the co untry and thus may no t reflect a co mplete picture o f the co untry

* Figures in the table 2 are restricted to availability of various dates required for calculation. Thus they may not adequately reflect cases with missing dates for various timelines.

%

s peci mens tes ted for s erol ogy

of s peci mens

recei ved i n the l a bora tory

% s erol ogy res ul ts reported w/i n 4 da ys

of s peci men recei ved a t l a bora tory

Case classification (number)

Reporti ng ra te of di s ca rded

non-mea s l es non-rubel l a ca s es a t the na ti ona l l evel per 100,000 popn

% di s tri cts reporti ng a t

l ea s t 2 di s ca rded

non-mea s l es non-rubel l a

ca s es per 100,000 popn

Mea s l es i nci dence1

per mi l l i on

popn

% s erum s peci mens recei ved a t l a bora tory w/i n 5 da ys of col l ecti on

Rubel l a i nci dence2

per mi l l i on

popn

Mea s l es Rubel l a

D

is

ca

rd

e

d

n

o

n

-m

e

a

sl

e

s

n

o

n

-ru

b

e

ll

a

c

a

se

s

P

e

n

d

in

g

c

la

ss

if

ic

a

ti

o

n

Countries

Number of s us pected mea s l es

ca s es % s us pected ca s es wi th a dequa te i nves ti ga ti

on i ni ti a ted

w/i n 48 hours of noti fi ca ti on

% s us pected ca s es wi th s erum s peci mens

col l ected Number of

s erum s peci mens recei ved i n l a bora tory

La

b

o

ra

to

ry

-c

o

n

fi

rm

e

d

E

p

id

e

m

io

lo

g

ic

a

ll

y-co

n

fi

rm

e

d

C

li

n

ic

a

ll

y-co

m

p

a

ti

b

le

La

b

o

ra

to

ry

-c

o

n

fi

rm

e

d

E

p

id

e

m

io

lo

g

ic

a

ll

y-co

n

fi

rm

e

d

Bangladesh 1,141 95 96 1,091 100 91 89 325 12 10 40 2 646 106 1.27 19 6.82 0.83

Bhutan 48 98 100 47 62 98 66 9* 0 0 1 0 38 0 15.63 50 37.02 4.11

DPR Korea 0 0 0 0 0 0 0 0 0 0 0 0.00 ND 0.00 0.00

India3 _9,153 ₀ ₃₃ _2,720 ₈₃ ₅₂ ₃₂ ₉₈₃ ₂₆ ₀ ₁₂₃ ₀ ₂₇₀ _7,751 _0.06 ₁ _2.41 _0.29

Indonesia4

656 0 100 655 98 95 90 133 0 1 193 0 293 36 0.36 4 1.64 2.37

Maldives 8 38 88 7 71 100 57 0 0 0 0 0 7 1 6.72 15 0.00 0.00

Myanmar 53 87 53 28 86 100 96 27 0 0 0 0 19 7 0.12 2 1.68 0.00

Nepal 289 99 96 175 76 91 0 13 0 5 5 0 149 117 1.67 23 2.02 0.56

Sri Lanka 37 89 81 28 89 100 64 1 0 2 0 0 32 2 0.48 4 62.00 0.42

Thailand 755 34 89 632 74 97 53 288 4 160 9 0 275 19 1.37 ND 22.60 0.45

Timor-Leste 58 97 97 56 102 88 86 0 0 0 2 0 48 8 12.07 23 0.00 5.03

SEAR 12,198 15 49 5,439 87 73 53 1,779 42 178 373 2 1,777 8,047 0.09 3.28 0.61

1

Includes labo rato ry-co nfirmed, epidemio lo gically-linked and clinically-co nfirmed measles cases 4

A lso includes the cases fro m enhanced measles case-based surveillance. ND=No data

2_{Includes labo rato ry-co nfirmed and epidemio lo gically-linked rubella cases}

* Impo rted cases

3 Case based surveillance is in the pro cess o f expansio n to all o ver the co untry and thus may no t reflect a co mplete picture o f the co untry

* Figures in the table 1 are restricted to availability of various dates required for calculation. Thus they may not adequately reflect cases with missing dates for various timelines.

%

s peci mens tes ted for s erol ogy

of s peci mens

recei ved i n the l a bora tory

% s erol ogy res ul ts reported w/i n 4 da ys

of s peci men recei ved a t l a bora tory

Case classification (number)

Reporti ng ra te of di s ca rded

non-mea s l es non-rubel l a ca s es a t the na ti ona l l evel per 100,000 popn

% di s tri cts reporti ng a t

l ea s t 2 di s ca rded

non-mea s l es non-rubel l a

ca s es per 100,000 popn

Mea s l es i nci dence1

per mi l l i on

popn % s erum

s peci mens recei ved a t l a bora tory w/i n 5 da ys of col l ecti on

Rubel l a i nci dence2

per mi l l i on

popn Mea s l es Rubel l a

D

is

ca

rd

e

d

n

o

n

-m

e

a

sl

e

s

n

o

n

-ru

b

e

ll

a

c

a

se

s

P

e

n

d

in

g

c

la

ss

if

ic

a

ti

o

n

Countries

Number of s us pected mea s l es

ca s es % s us pected ca s es wi th a dequa te i nves ti ga ti

on i ni ti a ted

w/i n 48 hours of noti fi ca ti on

% s us pected ca s es wi th s erum s peci mens

col l ected Number of

(2)

Vol. 22,

Week 16, 2018

Vaccine Preventable Disease Surveillance Bulletin

Page 2

Table 3: Classification of AFP Cases and Key Surveillance Indicators, 2017-2018 (data as of 23 April 2018)

Table 4: Intratypic Differentiation (ITD) of Isolates from AFP Cases, 2017-2018 (data as of 23 April 2018)

T

o

ta

l

>

9

0

D

a

y

s

3

T

o

ta

l

>

9

0

D

a

y

s

3

Bangladesh

1 363

0

1 347

16

2.74

2.70

98

99

363

0

239

124

1

2.39

1.57

99

Bhutan

9

0

8

1

India

39 339

0

23

38 535

781

8.97

8.79

86

98

8 512

0

6 713

1 799

194

6.31

4.98

87

98

Indonesia

1 689

0

2

1 557

130

2.40

2.21

82

97

292

0

204

88

12

1.35

0.94

82

97

Maldives

7

0

6

1

67

27

0

3.52

2.51

95

100

Sri Lanka

70

0

69

1

1.29

1.27

84

100

16

0

14

2

0

0.96

0.84

69

94

Thailand

198

0

179

19

1.71

1.55

68

95

15

0

15

4

0.42

0.00

87

100

Tim or-Leste

3

0

1

2

1

0.65

0.22

33

100

0

C

a

s

e

s

W

il

d

P

o

li

o

v

ir

u

s

C

a

s

e

s

V

a

c

in

e

D

e

ri

v

e

d

P

o

li

o

v

ir

u

s

C

a

s

e

s

C

o

m

p

a

ti

b

le

D

is

c

a

rd

e

d

(

N

o

n

-p

o

li

o

A

F

P

)

Pending

A

F

P

R

a

te

Case Classification

1

AFP Rates

2

Specim en

1

All countries are using the virologic classification scheme.

C

o

m

p

a

ti

b

le

D

is

c

a

rd

e

d

(

N

o

n

-p

o

li

o

A

F

P

)

Pending

A

F

P

R

a

te

N

o

n

-P

o

li

o

A

F

P

R

a

te

%

w

it

h

2

s

p

e

c

.,

a

t

le

a

s

t

2

4

h

rs

a

p

a

rt

,

w

/i

n

1

4

d

a

y

s

N

o

n

-P

o

li

o

A

F

P

R

a

te

%

w

it

h

2

s

p

e

c

.,

a

t

le

a

s

t

2

4

h

rs

a

p

a

rt

,

w

/i

n

1

4

d

a

y

s

%

w

it

h

a

n

y

s

p

e

c

im

e

n

A

F

P

C

a

s

e

s

W

il

d

P

o

li

o

v

ir

u

s

C

a

s

e

s

V

a

c

in

e

D

e

ri

v

e

d

P

o

li

o

v

ir

u

s

C

a

s

e

s

Country

2

AFP rates per 100,000 children aged <15 years using population figures provided by member countries (AFP cases > 15 years of age or missing age information are excluded).

%

w

it

h

a

n

y

s

p

e

c

im

e

n

W

il

d

V

a

c

in

e

W

il

d

V

a

c

in

e

V

D

P

V

W

il

d

V

a

c

in

e

<7 Days

>7

days Wil

d

V

a

c

in

e

W

il

d

V

a

c

in

e

V

D

P

V

W

il

d

V

a

c

in

e

<7 Days

>7 days

Bangladesh IPH, Dhaka 20 0 8 0 0 0 0 7 5 0 0 0 0 0 3 0 0 0 0 0 0 3 0 0 0 0 0 0

Bhutan NIH, Bangkok 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

DPR Korea NPL, Pyongyong 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

BJMC, Ahmedabad 231 0 78 0 0 0 0 65 79 9 0 0 0 0 111 0 25 0 0 0 0 30 54 1 0 0 1 0

NIV, Bengaluru 151 0 58 0 0 0 0 33 45 15 0 0 0 0 63 0 13 0 0 0 0 22 25 2 0 0 0 1

ERC, Mumbai 159 0 51 0 0 0 0 48 39 21 0 0 0 0 69 0 16 0 0 0 0 29 23 1 0 0 0 0

SGPGI, Lucknow 288 0 59 0 0 0 0 99 64 25 41 0 0 0 110 0 31 0 0 0 0 40 36 1 0 0 2 0

KIPM, Chennai 50 0 10 0 0 0 0 26 14 0 0 0 0 0 47 0 13 0 0 0 0 16 18 0 0 0 0 0

NCDC, Delhi 202 0 56 0 0 0 0 88 50 8 0 0 0 0 89 0 29 0 0 0 0 31 29 0 0 0 0 0

IoS, Kolkatta 175 0 55 0 0 0 0 41 57 19 3 0 0 0 82 0 23 0 0 0 0 23 32 1 1 0 2 0

CRI, Kasauli 22 0 11 0 0 0 0 6 5 0 0 0 0 0 14 0 3 0 0 0 0 3 7 0 0 0 0 1

1 278 0 378 0 0 0 0 406 353 97 44 0 0 0 585 0 153 0 0 0 0 194 224 6 1 0 5 2

Bio Farma, Bandung 2 0 0 0 0 0 0 2 0 0 0 0 0 0 0

NIHRD, Jakarta 3 0 1 0 0 0 0 0 2 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 2

PHL, Surabaya 1 0 0 0 0 0 0 1 0 0 0 0 0 0 2 0 0 0 0 0 0 0 2 0 0 0 0 0

6 0 1 0 0 0 0 3 2 0 0 0 0 0 4 0 0 0 0 0 0 0 2 0 0 0 0 2

Myanm ar NHL, Yangon 6 0 1 0 0 0 0 4 1 0 0 0 0 0 0

Nepal NIH, Bangkok 5 0 0 0 0 0 0 3 2 0 0 0 0 0 0

Sri Lanka MRI, Colombo 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

Thailand NIH, Bangkok 5 0 2 0 0 0 0 3 0 0 0 0 0 0 0

1 320 0 390 0 0 0 0 426 363 97 44 0 0 0 592 0 153 0 0 0 0 197 226 6 1 0 5 4

Polio 3

V

a

c

in

e

m

ix

tu

re

N

P

E

V

b

y

P

C

R

N

E

V

Country of

Case ITD Labs

2017 2018

Intratypic Differentiation results Results

pending

Intratypic Differentiation results Results

pending

A

F

P

c

a

s

e

s

re

fe

rr

e

d

fo

r

IT

D

Indonesia Total

TOTAL

N

P

E

V

b

y

P

C

R

N

E

V

N

e

g

a

ti

v

e

India

India Total

Indonesia

N

e

g

a

ti

v

e

A

F

P

c

a

s

e

s

re

fe

rr

e

d

fo

r

IT

D

Polio 1 Polio 2 Polio 3

V

a

c

in

e

m

ix

tu

re